Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13728990 | 1.00 | TLR7 (0.42) | TLR7NUDT1SERPINA3KMT2ACYP2E1 | |
| SCHEMBL13728634 | 1.00 | TLR7 (0.42) | TLR7NUDT1SERPINA3KMT2ACYP2E1 | |
| SCHEMBL13727022 | 1.00 | TLR7 (0.42) | TLR7NUDT1SERPINA3KMT2ACYP2E1 | |
| SCHEMBL14307926 | 0.95 | TLR7 (0.39) | TLR7NUDT1SERPINA3BTN3A1 | |
| SCHEMBL13727046 | 0.93 | TLR7 (0.41) | TLR7NUDT1SERPINA3BTN3A1 | |
| SCHEMBL13728931 | 0.93 | TLR7 (0.42) | TLR7NUDT1 | |
| SCHEMBL13727668 | 0.93 | TLR7 (0.42) | TLR7NUDT1 | |
| SCHEMBL13728622 | 0.93 | TLR7 (0.42) | TLR7NUDT1 | |
| SCHEMBL13728985 | 0.93 | TLR7 (0.42) | TLR7NUDT1 | |
| SCHEMBL13727673 | 0.92 | TLR7 (0.41) | TLR7NUDT1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008682-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | TLR7 1/4885NUDT1 3020/4885SERPINA3 3298/4885 |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885NUDT1 2864/4885SERPINA3 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.